Matthias Steger
CEO
Endogena
Endogena Therapeutics develops small-molecule drugs that selectively regulate adult stem and progenitor cells to facilitate tissue repair and regeneration, targeting degenerative diseases such as retinitis pigmentosa and age-related macular degeneration. The company addresses the high unmet medical need for effective treatments in conditions that lead to vision loss and other age-related disorders.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$35.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many degenerative diseases, such as retinitis pigmentosa and age-related macular degeneration, lack effective treatments, leading to vision loss and other debilitating conditions. Current therapeutic options often fail to address the underlying causes of tissue degeneration and have limited regenerative capabilities. There is a significant unmet need for therapies that can restore tissue function and reverse the effects of these progressive diseases.
Solution
Endogena Therapeutics is a clinical-stage biotechnology company focused on discovering and developing endogenous regenerative medicines. The company's approach involves using small-molecule drugs to selectively regulate adult stem and progenitor cells, stimulating tissue repair and regeneration. By harnessing the body's innate regenerative abilities, Endogena aims to develop therapies that can reverse the course of degenerative diseases. Their pioneering approach leverages cutting-edge knowledge of molecular pathways that regulate retinal stem cells and retinal pigment epithelial cells to address diseases such as retinitis pigmentosa and age-related macular degeneration.
Target Audience
Endogena's primary target audience includes patients suffering from degenerative diseases with high unmet medical needs, such as retinitis pigmentosa, age-related macular degeneration, and idiopathic pulmonary fibrosis, as well as the ophthalmologists and pulmonologists who treat them.
Features
- Small-molecule drugs designed to selectively regulate adult stem and progenitor cells
- Focus on endogenous regeneration, activating the body's innate repair mechanisms
- Drug discovery approach based on phenotypic, functional screening to identify molecules for controlled tissue repair
- Pipeline targeting degenerative diseases of the eye, including retinitis pigmentosa and age-related macular degeneration
- EA-2353, a drug in clinical studies for retinitis pigmentosa, with potential to reverse vision loss
- Investigational therapies for idiopathic pulmonary fibrosis
- FDA Fast Track designation for EA-2353 in the treatment of retinitis pigmentosa